SOURCE: ViroCyt, LLC

ViroCyt, LLC

ViroCyt, LLC

November 12, 2014 09:30 ET

ViroCyt Wins Colorado BioScience Association's "Rising Star" Award

BOULDER, CO--(Marketwired - Nov 12, 2014) - ViroCyt, LLC, the leader in rapid virus quantification, announced today that it has received the "Rising Star" award from the Colorado Bioscience Association after being nominated as one of three companies in the category.

"The Colorado BioScience Association's Rising Star award recognizes early stage growth companies that have made great strides over the current year. ViroCyt was selected not only because their innovations are changing the landscape of virus detection technologies, but also because they are committed to delivering meaningful improvements to vaccines and antiviral development," said April Giles, President and CEO of the Colorado BioScience Association.

"We are delighted to have been recognized by the industry as an innovator, especially with the growing awareness of the threat posed by emerging infectious diseases, such as Ebola, and the critical need to accelerate the pace of vaccine development," stated Robert Kline, President and CEO of ViroCyt. "By replacing outdated and time-consuming methods, the Virus Counter technology is shortening the time to market for these life-saving products."

The third generation of the Virus Counter, the 3100, was launched in March of 2014 with the primary goal of providing a system capable of withstanding the rigors of biologics manufacturing environments. This includes increased stability, GMP compliance and the addition of an autosampler for walkaway processing of up to 96 samples per run. Virus Counters are in use at many of the world's top companies, regulatory agencies, government research institutes and universities. Examples include Sanofi Pasteur, Protein Sciences, GE Healthcare, CBER/FDA, NIAID and The University of Maryland.

About ViroCyt, LLC

ViroCyt, LLC was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at http://www.virocyt.com.

Contact Information

  • Michael Artinger
    Vice President, Marketing & Strategic Partnering
    ViroCyt, LLC
    +1-720-599-3700
    Email Contact